Resmed launches AirConnect Dx in the UK to help NHS sleep services reduce diagnostic backlogs

NHS service evaluations of AirConnect Dx show up to 97% reduction in referral-to-diagnosis time for suspected sleep apnoea¹

London, May 21, 2026 - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the launch of AirConnect Dx in the UK, a digital, service-based solution designed to increase NHS sleep services diagnostic capacity and support faster access to diagnosis for people with suspected obstructive sleep apnoea (OSA).

Across the UK, NHS sleep services are facing growing referral volumes, workforce pressures and diagnostic backlogs. According to NHS England's Monthly Diagnostics Data, more than 30,000 people are currently waiting for sleep studies, with around a quarter of patients waiting six weeks or longer for testing², delaying access to care and increasing pressure on clinical teams.

AirConnect Dx is designed to help address these challenges by enabling earlier diagnosis of suspected OSA, so people can start appropriate treatment sooner. Early NHS service evaluations across three pilot sites, spanning rural, mixed and urban care settings, demonstrated the impact of AirConnect Dx's fully digital diagnostic pathway¹. The findings are based on service-level operational measures:

• 90-97% reduction in referral-to-diagnosis time - from approximately 3-12 months under standard care to 8-21 days with the digital pathway
• 95-99% reduction in screening duration
• Retest rates reduced to 0-7%, from 10-18% within traditional pathways
• Up to 3x increase in diagnostic capacity using existing staff capacity

By saving healthcare professional time and reducing operational burden, AirConnect Dx can help ease pressure on overstretched teams and redirect staff time toward higher-value clinical activities, including patient consultations, treatment initiation and ongoing care.

"Sleep services are under immense pressure, and long diagnostic waiting times can impact patients' health and quality of life," said Theresa Shapland, UK Country Manager, Resmed. "AirConnect Dx is designed to simplify and scale the diagnostic pathway by supporting NHS teams in moving patients from referral to diagnosis more efficiently, helping accelerate access to care."

"Implementing AirConnect Dx has transformed our diagnostic pathway," said Julia Roberts, Respiratory Physiology Service Manager, Betsi Cadwaladr University Health Board, Bangor Sleep Clinic, North Wales. "We have significantly cut waiting times and simplified the process for both patients and staff. Most importantly, patients are getting treated before their condition worsens."

"When I was told I might have sleep apnoea, I stopped driving long distances immediately. As a programme manager for a large logistics provider covering the country, that had a real impact on my work and added hours to every journey. I just wanted to get it sorted as quickly as possible," said Kevin, who was diagnosed through the NHS pilot pathway.

AirConnect Dx is now available to NHS sleep services across the UK. The solution supports a streamlined digital diagnostic pathway by integrating referral, screening, home sleep testing, reporting, logistics and patient support in a single, coordinated service under clinical oversight.

In the UK, OSA affects an estimated 8 million people³, a number projected to rise to nearly 12 million by 2050.⁴ If left untreated, OSA can significantly impact health and quality of life, increasing the risk of high blood pressure, heart disease, type 2 diabetes and stroke.⁵ As prevalence rises, the gap between demand for diagnosis and available capacity is expected to widen, underscoring the need for scalable, technology-enabled diagnostic solutions like AirConnect Dx.

AirConnect Dx is the first module within Resmed's AirConnect suite of provider care management services, designed to support more efficient, scalable delivery of sleep and respiratory care.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.

Contacts

For Media
Julia Moser
[email protected]
[email protected]

For Investors
Salli Schwartz
[email protected]
[email protected]